What are the risk factors for supraventricular tachycardia (SVT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Risk Factors for Supraventricular Tachycardia

The primary risk factors for SVT include female sex (2-fold increased risk), advancing age, congenital heart disease (10-20% prevalence), structural heart disease, and specific precipitating conditions including surgery, acute illness, and underlying cardiac comorbidities. 1

Demographic Risk Factors

Age

  • Mean age of SVT onset is 57 years, with a broad range from infancy to over 90 years 1
  • The incidence of atrial flutter increases dramatically with age: from 5 per 100,000 in those under 50 years to 587 per 100,000 over age 80 1
  • Age of tachycardia onset differs by mechanism: AVNRT typically presents at 32±18 years versus AVRT at 23±14 years 1
  • Older patients are more prone to syncope or presyncope with SVT, independent of heart rate 2

Sex

  • Female sex confers a 2-fold greater relative risk of paroxysmal SVT (RR=2.0; 95% CI 1.0-4.2) compared to males 1
  • Approximately 67.5% of PSVT patients are female 3
  • Atrial flutter is 2.5 times more common in men 1

Structural and Congenital Heart Disease

Adult Congenital Heart Disease (ACHD)

  • SVT occurs in 10-20% of ACHD patients, representing the highest-risk population 1, 4
  • ACHD-associated SVT carries significantly increased risk of heart failure, stroke, and sudden cardiac death 1, 4
  • Specific high-risk lesions include: 5
    • Ebstein's anomaly (strongly associated with accessory pathways and Mahaim fibers)
    • Tetralogy of Fallot
    • Transposition of the great arteries
    • Atrial septal defects
  • Single-ventricle physiology patients have particularly complex SVT substrates, with 60% having twin AV nodes 6
  • Right atrial isomerism patients have 72.2% prevalence of twin AV nodes 6

Acquired Structural Heart Disease

  • Heart failure, hypertension, and chronic lung disease are associated with increased SVT risk 1
  • Ischemic heart disease increases SVT susceptibility 1
  • Only 1.7% of atrial flutter cases occur without structural cardiac disease or precipitating causes (lone atrial flutter) 1

Precipitating Conditions and Comorbidities

Acute Precipitants

  • In approximately 60% of atrial flutter cases, SVT occurs for the first time in association with specific precipitating events: 1
    • Major surgery
    • Pneumonia
    • Acute myocardial infarction
  • Postoperative junctional tachycardia occurs in 2-10% of young patients undergoing intracardiac surgery 1

Chronic Comorbidities

  • Heart failure 1
  • Hypertension 1
  • Chronic obstructive pulmonary disease 1

Electrophysiologic Substrates

Accessory Pathways

  • Patients with Wolff-Parkinson-White syndrome and pre-excitation on ECG are at risk for significant morbidity and possibly sudden death 4
  • Manifested pre-excitation is present in 10% of single-ventricle CCHD patients 6
  • Accessory pathways are particularly common in Ebstein's anomaly 5

Dual AV Nodal Pathways

  • Dual AV nodal properties occur with increased probability in specific congenital heart defects 5
  • Twin AV nodes are present in 60% of single-ventricle patients 6

Special Populations

Fetal SVT

  • Sustained fetal SVT puts the fetus at risk of cardiovascular collapse manifested by hydrops 1
  • Persistent SVT with hydrops carries high mortality rate 1

"Lone" PSVT Patients

  • Younger than those with other cardiovascular disease (mean age 37 vs 69 years) 1
  • Faster heart rates (186 vs 155 bpm) 1
  • More likely to present first to emergency room (69% vs 30%) 1

Clinical Pitfalls

Common diagnostic delay occurs due to misdiagnosis as anxiety or panic disorder 7, emphasizing the importance of maintaining high clinical suspicion when patients report palpitations, particularly in young women with episodic symptoms.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Taquicardia Auricular y Síncope

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Complications of Supraventricular Tachycardia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Congenital heart defects in adulthood : Supraventricular tachycardia].

Herzschrittmachertherapie & Elektrophysiologie, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.